Abstract Dishevelled (DVL) proteins are components of the Wnt signalling pathways, and increased expression is associated with various malignancies. Information on DVLs in chronic lymphatic leukaemia (CLL) is limited. The aim of the present study was to investigate the role of DVLs in CLL cells and association with Wnt pathways downstream of ROR1. DVL1, 2 and 3 were exclusively expressed in CLL cells as compared to normal peripheral blood mononuclear cells (PBMCs). The expression of DVL1 and DVL3 proteins was significantly more pronounced in progressive than in non-progressive disease (p < 0.01), whereas the level of DVL2 was significantly higher in non-progressive as compared to progressive disease (p < 0.001). Treatment of CLL cells with anti-ROR1 specific monoclonal antibodies induced dephosphorylation of ROR1 as well as of tyrosine and serine residues of both DVL2 and DVL3. However, gene silencing of DVLs in the CLL cell line (EHEB) did not induce detectable apoptosis. Non-progressive CLL patients had a different protein activity pattern with regard to Wnt signalling pathway proteins as GSK-3β, β-catenin and AKT as compared to progressive disease. The DVL2 protein may play a role in the activation of signalling pathways in CLL during early stages of the disease, while DVL1 and 3 may have a role in later phases of the leukaemia.
Introduction
Chronic lymphocytic leukaemia (CLL) is characterized by the accumulation of mature B cells with the phenotype CD19+/ CD5+/CD23+, which have an increased proliferative activity and a defect in apoptotic machinery [1] . The clinical course is highly variable. Advanced clinical stage and high-risk molecular prognostic characteristics (e.g. cytogenetic abnormalities such as p53 abnormalities or complex karyotype, unmutated IgVH, expression ZAP70 and CD38) are associated with disease progression and short survival [2] .
Recent studies have demonstrated overexpression of the receptor tyrosine kinase-like orphan receptor ROR1 in CLL [3] [4] [5] . ROR1 is a transmembrane protein of the receptor tyrosine kinase (RTK) family and related to the Trk-RTK, musclespecific kinase (MuSK) and neurotrophic tyrosine kinase (NTRTK) receptor families [6] . ROR1 is normally expressed during the embryonic development and plays a key role in skeletal, lung and neural organogenesis, but is repressed in adult tissues [7] . ROR1 is of importance for cell proliferation, survival, differentiation, metabolism and polarity [8] and for tumour-like behaviour as migration and invasiveness [9] . In haematological malignancies, ROR1 is upregulated in e.g. chronic lymphocytic leukaemia [3] [4] [5] , acute lymphocytic leukaemia [10] and mantle cell lymphoma [11] .
Proteins of the wingless-type MMTV integration site family (Wnt) have been suggested to be ligands for ROR receptors [8, 12] . Wnt signalling pathways play pivotal roles during embryogenesis, but are progressively turned off in differentiated cells [13] . Wnt signalling pathways seem to be stepwise involved in tumourigenesis [14] . Multiple Wnts (Wnt-3, Wnt-5b, Wnt-6, Wnt-14, Wnt-16) and Frizzled (Fzd) receptors (Fzd-3) as well as the lymphoid enhancerbinding factor 1 (LEF1) messenger RNAs (mRNAs) have been shown to be elevated in CLL cells compared to normal B cells [15] .
The Wnt signalling cascade constitutes two major pathways: the β-catenin-dependent (canonical) and -independent (non-canonical) pathways. In the β-catenin-dependent signalling, Wnt ligands bind to Fzd receptors in the presence of the low-density lipoprotein receptor-related protein 6 (LRP6), inhibiting β-catenin degradation by glycogen synthase kinase 3β (GSK-3β) through dishevelled proteins (DVL1, 2, 3). β-catenin then remains stable, accumulates in the cytoplasm and translocates to the nucleus, where β-catenin activates the target genes through interaction with the transcription factors Tcell factor (TCF) and LEF1 respectively. Accumulation of β-catenin by inhibiting GSK-3β or LEF1 increased the survival of CLL cells in vitro, whereas inhibition of Wnt signalling induced apoptosis of CLL cells, indicating that this pathway might play a role in the survival of CLL cells [16] .
DVLs are upstream mediators of both Wnt signalling pathways [17] . DVLs were originally identified based on the phenotype of disorientation in the body and wing hairs of Drosophila [18] . Three DVL homologues (DVL1, 2, 3) have been identified in humans and mice. The proteins consist of about 750 amino acids and display a high sequence homology. Genes of DVL1, DVL2 and DVL3 are expressed early during mouse embryogenesis [19] . DVL knockout mice (DVL2 −/− and DVL3
−/−
) died prenatally [20, 21] . Wnt/Fzd interactions activate several signalling pathways [22] . In the β-catenin-dependent pathway, DVLs act as scaffold proteins bridging together the receptor and downstream signalling molecules [23] . Phosphorylated LRP5/6 and activated DVLs are important for recruiting axin to the cell membrane and to the cytosolic stabilization of β-catenin [16] . In the β-catenin-independent pathway, DVLs play a role in the downstream signalling of planar cell polarity (PCP) as well as the Wnt/calcium pathway [24] . Recruitment of DVLs induced activation of both ROCK (Rho-associated protein kinase) and protein kinase C (PKC), which triggered the activation of Ca 2+ -calmodulindependent calcineurin and CAMKII (Ca 2+ -calmodulin-dependent kinase II) signalling [25] .
ROR1 has been shown to be of importance for the survival of CLL cells [4, 5, 26] . Assuming that DVLs play a role in the downstream signalling of ROR1-associated Wnt pathways, we addressed the question of whether DVLs might be involved in the survival of CLL cells. The protein expression pattern of DVL1, 2 and 3 was studied in progressive and nonprogressive CLL patients and CLL cell lines.
Materials and methods

Patients and controls
Eighteen CLL patients (nine with progressive and nine with non-progressive disease) ( Table 1 ) and nine healthy agematched donors were included. Approval by the regional ethics committee (www.epn.se) was obtained as well as oral and written informed consent from the donors in accordance with the Helsinki Declaration. The diagnosis of CLL was established as previously described [27] . Progressive (P) disease was defined as progression during the preceding 3 months in anaemia (haemoglobin <100 g/l), thrombocytopenia (<100 × 10 9 ) and size of spleen/liver/lymph nodes or in more than twice the lymphocyte count. Patients that did not meet these criteria were considered to have non-progressive (NP) disease [28] , in which all patients were untreated before the bloods were taken. FISH analyses and p53 mutation tests of CLL cells were done at the Department of Clinical Genetics at the Karolinska University Hospital, Stockholm (Table 1) . Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Hypaque (GE Healthcare, Uppsala, Sweden) density centrifugation according to manufacturer's instructions. B cells were purified from healthy donors using a magnetic bead cell separation system (MiniMACS) (Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, PBMCs were isolated by Ficoll-Hypaque. B cells were enriched using immunomagnetic MACS beads coated with anti-CD19 according to manufacturer's instructions. B cell purity was >95 % (flow-cytometry).
Cell lines
The CLL-derived cell lines, EHEB, CII, I83-E95 and 232-B4, were used as well as the Lukas (Burkitt lymphoma-derived) and the Jurkat (T cell lymphoma) cell lines. All cell lines were obtained from the American Type Culture Collection and cultured in RPMI 1640 (Invitrogen, CA, USA) with 10 % heatinactivated FBS (Invitrogen) and penicillin/streptomycin at 37°C in humidified air with 5 % CO 2 .
Western blot
PBMCs were lysed in buffer containing 1 % Triton X-100, 150 mM NaCl, 50 mM Tris-HCl, 5 mM EDTA, 1 % protease inhibitor cocktail (Sigma-Aldrich Corp., Saint Louis, MO, USA) and phosphatase inhibitors (Roche Ltd, Basel, Switzerland) on ice for 30 min and centrifuged at 13, 000 rpm. Supernatants were collected and protein concentration measured by Thermo Scientific BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). About 15 μg of the lysate was loaded onto 10 % Bis-Tris SDS-PAGE gel (Invitrogen, Carlsbad, CA, USA) and run at 135 V for 2 h.
Protein was transferred to immobilon-PVDF membranes (Millipore Corporation, Billerica, MA, USA) and blotted at 35 V for 1.5 h in transblot cell (Invitrogen) at room temperature. Membranes were blocked in 5 % bovine serum albumin (BSA) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in TBS with 0.1 % Tween 20 (TBS-T) at room temperature for 2 h. Membranes were probed with the respective primary antibodies overnight at 4°C and washed five times for 10 min in TBS-T at room temperature and then with the secondary antibody conjugated with peroxidase (Dako Cytomation, Glostrup, Denmark) for 1.5 h in 5 % non-fat milk in 0.1 % TBS-T at room temperature. The membranes were washed five times and developed using the ECL chemiluminescence detection system (GE Healthcare, Uppsala, Sweden). The following antibodies were used: DVL2, DVL3, pPKC, PKC, pan pAKT, AKT, ERK, pGSK-3α, GSK-3α, pan pGSK-3β, GSK-3β and β-catenin (Cell Signaling Technology, Danvers, MA, USA), DVL1, DVL2 and DVL3 (Santa Cruz Biotechnology) as well as antiphospho-tyrosine mAb (clone 4G10) and anti-phosphoserine mAb (clone 4A4) (Millipore Corporation, Bedford, MA, USA). For loading control, membranes were probed for β-actin (Sigma-Aldrich Corp., Saint Louis, MO, USA).
Immunoprecipitation
Immunoprecipitation (IP) was done with DVL1, DVL2 and DVL3 antibodies respectively using Dynabeads protein A and G (Invitrogen Dynal, Oslo, Norway) according to the manufacturer's instructions. Immunoprecipitated proteins were subjected to blotting under reducing conditions. Membranes were probed with anti-phospho-tyrosine and anti-phospho-serine antibodies (Millipore).
Dephosphorylation of protein
We have previously shown that our anti-CRD ROR1 mouse monoclonal antibody could induce dephosphorylation of ROR1 [29] as well as of ROR1 associated downstream signalling molecules as PI3K/AKT/mTOR/CREB [29] . PBMCs from CLL patients were treated with the anti-ROR1 antibody (CRD-1D8) (IgG2A) (10 μg/ml) in Aim V medium (Life Technologies, Carlsbad, CA, USA) at 37°C in humidified air with 5 % CO 2 . After 30 min of incubation, cells were lysed in a buffer containing 1 % Triton X-100, 150 mM NaCl, 50 mM Tris-HCl, 5 mM EDTA, 1 % protease inhibitor cocktail (Sigma-Aldrich Corp., Saint Louis, MO) and phosphatase inhibitors (Roche Ltd, Basel, Switzerland) on ice for 30 min and centrifuged at 13,000 rpm. Lysed cells were collected and Western blot was performed. A rabbit polyclonal pRor-1 antibody against the phosphorylated TK domain of ROR1 was used to detect phosphorylated ROR1 [30] .
Lysates were also immunoprecipitated using DVL2 and DVL3 antibodies and subjected to immunoblotting under reducing conditions. The membranes were probed with antiphospho-tyrosine and anti-phospho-serine antibodies (Millipore) . Immunoprecipitation of DVL1 probed with anti phospho-tyrosine and anti-phospho-serine antibodies in the dephosphorylation experiment could technically not be performed (data not shown).
Quantification of total and phospho-proteins
The level of phosphorylation was measured by analysing the intensity of phosphorylated proteins in relation to the respective total protein using the ImageJ 1.44p software (National Institutes of Health, USA). The expression of nonphosphorylated proteins was related to β-actin [29] .
siRNA transfection 6 CLL PBMCs/ml were transfected with 1 μM siRNA (Accell; Thermo Fisher Scientific) for 48 h at 37°C. After incubation, expression of DVL genes was determined by qPCR analysis. siRNA transfected cells were also used in the MTT assay (see below).
qPCR analysis
Total RNA (2 μg) was used to synthesize single-strand complementary DNA (cDNA) by the Superscript II reverse transcriptase system and Oligo(dT) [12] [13] [14] [15] [16] [17] [18] according to the manufacturer's instructions (Life Technologies). TaqMan gene expression assays were performed by the FAM dye labelling system according to the manufacturer's instructions using Hs00182896_m1 (DVL1), Hs00182901_m1 (DVL2), Hs00610263_m1 (DVL3) and the endogenous control gene GAPDH (Hs02758991_g1) (Life Technologies). Quantitative PCR (qPCR) was performed in a total volume of 10 μl in a 384-well plate thermal cycler ABI 7900 (Life Technologies), and the relative expression of genes (CT values) was determined. After incubation, 20 μl of MTT reagent (5 mg/ml) was added. The plate was left for 4 h at 37°C. The reactions were stopped with MTT solvent (10 % SDS in 0.01 N HCl). Optical density (OD) was read in a Multiskan FC microplate reader (Thermo Scientific) at 595 nm.
Statistics
Statistical analysis was done by using GraphPad Prism version 5 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical calculation of normalized intensity values for each protein was done by one-way analysis of variance (ANOVA) test followed by post-hoc Tukey's honest significant difference test (HSD). The cut-off for significance was set to p < 0.05.
Results
Expression of DVL proteins
DVL1, DVL2 and DVL3 were highly expressed in CLL cells, but not detectable in B cells of healthy donors (Fig. 1a, b) . The relative expression of DVL1 and DVL3 was significantly higher in progressive compared to non-progressive disease (p < 0.01), while DVL2 was higher expressed in nonprogressive compared to progressive disease (p < 0.001). The CLL cell lines EHEB, CII, I83-E95 and 232-B4 as well as the Lukas and Jurkat cell lines expressed DVL2 and DVL3, while DVL1 was only weakly expressed (data not shown).
Phosphorylation of DVL proteins
DVL1, DVL2 and DVL3 proteins were immunoprecipitated using the respective antibodies and immunoblotted for phospho-tyrosine and phospho-serine. DVL1, DVL2 and DVL3 were phosphorylated at both serine and tyrosine residues (Fig. 2) . Incubation of CLL cells with an anti-ROR1 monoclonal antibody directed against the CRD region induced apoptosis of CLL cells preceded by dephosphorylation of ROR1 [30] . The anti-ROR1 antibody in addition to dephosphorylating ROR1 also dephosphorylated tyrosine and serine residues of DVL2 and DVL3 (Fig. 3) .
Expression of GSK-3β and β-catenin GSK-3β and β-catenin are key proteins in the Wnt canonical pathway. Phosphorylated GSK-3β was detected in CLL cells of all patients as well as in PBMCs of healthy donors (Fig. 4a) . Phosphorylation intensity of GSK-3β was significantly higher in progressive than in non-progressive disease (p < 0.01) as well as compared to healthy controls (p < 0.001) (Fig. 4b) . The expression of β-catenin varied between donors (Fig. 4c) , but in general, the expression intensity was significantly higher in CLL patients compared to healthy donors and more pronounced in non-progressive compared to progressive disease (Fig. 4d) .
Expression of PKC, AKT and GSK-3α
PKC, AKT and GSK-3α are regulators of the Wnt noncanonical (β-catenin-independent) pathway. Phosphorylation of PKC (Fig. 4e, f) and GSK-3α (Fig. 4g, h ) varied, and there was no statistically significant difference between CLL patients or in comparison to control donors. However, phosphorylation of AKT was significantly higher in CLL patients with non-progressive compared to progressive disease (p < 0.01) (Fig. 4i, j) . 
Silencing of DVL in the CLL-derived cell line EHEB
The apoptotic effect of DVL gene silencing was analysed using the CLL-derived EHEB cell line. siRNA transfection with DVL1, DVL2 and DVL3 was successful (Fig. 5 ), but no effect on cell survival was noted (data not shown).
Discussion DVL1, DVL2 and DVL3 proteins were highly expressed in CLL cells compared to normal PBMCs. The expression of DVL1 and DVL3 was more pronounced in progressive than in non-progressive disease, whereas the level of DVL2 was higher in non-progressive compared to progressive CLL. All three DVLs were expressed in the four CLL cell lines as well as in the Jurkat and Lukas cell lines. DVL1, 2 and 3 proteins were phosphorylated at both serine and tyrosine residues. There are two major Wnt-signalling pathways in mammalians: the canonical and non-canonical pathways. The canonical Wnt signalling pathway has been shown to be activated in embryonic and adult stem cells, but is progressively turned off in differentiated cells. However, in mature cells the canonical Wnt signalling pathway is activated during tumourigenesis and of importance for tumour cell proliferation and migration [31] . Activation is induced by binding of a Wnt ligand to a Frizzled receptor inducing phosphorylation of DVLs [32, 33] , which may activate downstream signalling proteins of significance for survival and proliferation [23] . In our study silencing of DVLs of the EHEB cell line (a CLL-derived cell line) and PBMCs of CLL patients did, however, not induce apoptosis, which may suggest that these proteins might not be of major importance for survival of CLL cells. We could also show the expression of other activated proteins of importance both for the canonical and non-canonical Ror-1/Wnt signalling pathways in CLL. Inhibition of ROR1 dephosphorylated DVL2 and 3 at both Ser/Thr and tyrosine residues. Grumolato et al. [34] showed that the canonical Wnt3a and non-canonical Wnt5a ligands specifically triggered the completely unrelated endogenous coreceptors LRP5/6 and ROR1/2 respectively through a common mechanism that involved their Wnt-dependent coupling binding to the Frizzled (Fzd) coreceptor and recruitment of shared components including dishevelled (DVL), axin and glycogen synthase kinase 3 (GSK3) proteins. Furthermore, AKT seems to be one of the key players in the non-canonical Wnt pathway [35] . Activation may promote survival of CLL cells [36] [37] [38] [39] . The present study also showed that AKT was activated in both progressive and non-progressive disease compared to healthy donors. Surprisingly, patients with non-progressive disease showed a significantly higher phosphorylation level of AKT as compared to patients with progressive disease, but phosphorylated PKC upstream of AKT did not differ significantly between CLL patients and healthy donors. The results may be consistent with those of others suggesting that Wnt5a triggers AKT phosphorylation via PI3K, but not via ERK or PKC [40] .
ROR1, Fzd receptors, multiple Wnts and LEF1 mRNAs have been found to be increased in CLL cells compared to healthy B cells [41] . Binding of Wnt ligands to Fzd receptors in the presence of the LRP6 coreceptor inhibited degradation of β-catenin by GSK-3β [35] . Accumulation of β-catenin in the cytoplasm and subsequent translocation to the nucleus may activate target genes through interaction with the transcription factors TCF and LEF1 regulating numerous target genes involved in cell cycle progression, adhesion and differentiation.
The non-canonical Wnt signalling may also be activated by ROR1 and/or other Frizzled receptors activating downstream signalling proteins, regulating e.g. cytoskeleton formation and cell adhesion. One of the downstream signalling pathways is PCP. Cellular polarization is essential for the function of many tissues. PCP signalling consists of two major groups of Ror-1 Ror-1 Fig. 6 In the absence of ROR1 and DVLs in normal B cells, the destruction complex comprising APC, axin-1 and GSK-3β controls the cellular level of beta-catenin by ubiquitination of β-catenin. In nonprogressive CLL, phosphorylated ROR1 contributes to phosphorylation of the highly expressed DVL2 as well as AKT, which inactivates GSK-3β and subsequently disrupts the destruction complex. β-catenin accumulates in the nucleus, regulating gene expression by binding to the TCF/LEF-1 DNA-binding proteins and promoting preferentially cell survival. In contrast to progressive CLL, phosphorylated ROR1 activates DVL1 and 3, disrupting the destruction complex and activating the Wnt/ PCP pathway, promoting preferentially proliferation and migration of CLL cells [49, 50] . Bold marks indicate a relatively higher expression of phosphorylated proteins and signalling activity comparing nonprogressive and progressive CLL proteins: the core PCP and the global module [42] . The core PCP genes encode functions of importance for molecular asymmetry within and between cells. These proteins are required for organization of multicellular structures, tissue remodelling, cellular polarization and movements. The global module includes the atypical cadherins, Ft and Ds, which interact heterophilically across membranes, as well as the Golgi protein four-jointed (Fj) modulating affinity by phosphorylation. It is not known whether the Ft/Ds module has a role upstream of the core PCP module or represents an independent system [43] . Many proteins downstream of PCP as the Rho family of GTPases or the JNK/p38 MAPK module are important effector molecules involved in e.g. adhesion and migration and thus are of significance in tumour invasion and metastasis [44] . Deregulated PCP signalling is implicated in tumour metastasis. A recent study in non-small cell lung cancer (NSCLC) (dishevelled-1 and dishevelled-3 affect cell invasion mainly through canonical and non-canonical Wnt pathway respectively and associate with poor prognosis in non-small cell lung cancer [45] ) showed that the expression of DVL3 was significantly higher in nodal metastases than in the primary tumours. Correlation between DVL3 and β-catenin was noted neither in primary tumours nor in metastases.
DVLs were not expressed in normal leucocytes. AKT was slightly phosphorylated as well as GSK-3β, which may regulate ubiquitination of β-catenin. In CLL, cell DVL2 was expressed. Based on the current and previous studies, we suggest a model for the interactions between DVLs, AKT, GSK-3β and β-catenin in CLL (Fig. 6) . In non-progressive CLL, AKT and DVL2 were highly phosphorylated, which may prevent GSK-3β to be phosphorylated. Inhibition of activation of GSK-3β by phosphorylated AKT and DVL2 may promote the accumulation of β-catenin and activation of TCF/LEFmediated transcription of genes, which might preferentially prolong survival of CLL cells [46, 47] . DVL1 and DVL3 were highly phosphorylated in progressive CLL, while AKT was slightly phosphorylated, which might prevent GSK-3β to be fully phosphorylated preferentially to support proliferation and migration. This is in agreement with Kaucka et al. [48] . Upregulation of the Wnt/PCP pathway has been shown to be significantly phosphorylated in progressive as compared to non-progressive CLL patients. Activation of both the canonical and non-canonical pathways in progressive CLL may not only prolong cell survival but also support proliferation and migration [49, 50] . The reason for the differential expression of DVL1, 2 and 3 in non-progressive and progressive is not clear [51] .
In conclusion, DVL proteins were highly overexpressed in CLL patients. Non-progressive CLL had a different activity pattern of the Wnt signalling pathways compared to progressive disease. The different DVL proteins' expression pattern might contribute to the altered signalling pathway profile during tumour progression. However, future studies are needed to understand the mechanism for and relevance of differential DVL expression and the association with Wnt signalling in the pathobiology of CLL.
